Daily Sepsis Research Analysis
Three impactful sepsis studies span therapeutics, prognosis, and antimicrobial stewardship. Structure-guided engineering of an Ang1 variant enhanced Tie2 binding and attenuated sepsis in mice, a promising endothelial-targeted therapy. Clinically, persistence of early systemic insults in severe sepsis-associated encephalopathy independently predicted mortality and delayed awakening, while fluconazole resistance in Candida parapsilosis candidemia was not linked to higher 30-day mortality but incre
Summary
Three impactful sepsis studies span therapeutics, prognosis, and antimicrobial stewardship. Structure-guided engineering of an Ang1 variant enhanced Tie2 binding and attenuated sepsis in mice, a promising endothelial-targeted therapy. Clinically, persistence of early systemic insults in severe sepsis-associated encephalopathy independently predicted mortality and delayed awakening, while fluconazole resistance in Candida parapsilosis candidemia was not linked to higher 30-day mortality but increased 1-year recurrence.
Research Themes
- Endothelial stabilization via Ang-Tie2 pathway as a sepsis therapy
- Early systemic insults driving outcomes in sepsis-associated encephalopathy
- Antifungal resistance and long-term outcomes in candidemia
Selected Articles
1. Development of a recombinant Ang1 variant with enhanced Tie2 binding and its application to attenuate sepsis in mice.
Using structure-guided design and molecular dynamics, the authors engineered an Ang1 variant with improved Tie2 binding and demonstrated attenuation of sepsis in mice. The work supports endothelial stabilization via Ang-Tie2 signaling as a therapeutic strategy.
Impact: Introduces a rationally engineered biologic targeting the Ang–Tie2 pathway with in vivo efficacy in sepsis, potentially opening a new therapeutic avenue addressing endothelial dysfunction.
Clinical Implications: While preclinical, Tie2-agonistic Ang1 variants could complement vasopressors and anti-inflammatory strategies by stabilizing the endothelium and limiting vascular leak in sepsis.
Key Findings
- Structure-guided identification of key Ang1 RBD residues enabled engineering of a variant with enhanced Tie2 affinity.
- The engineered Ang1 variant attenuated sepsis severity in mouse models.
- Molecular dynamics analyses supported the mechanistic basis for improved Ang1–Tie2 interactions.
Methodological Strengths
- Structure-guided protein engineering with molecular dynamics validation
- In vivo efficacy testing in sepsis mouse models
Limitations
- Preclinical animal data without human validation
- Dosing, pharmacokinetics, and safety are not detailed in the abstract
Future Directions: Advance to dose-finding and safety studies, validate efficacy in diverse sepsis models and comorbidities, and assess pharmacokinetics/immunogenicity before early-phase clinical trials.
The angiopoietin (Ang)-Tie axis, critical for endothelial cell function and vascular development, is a promising therapeutic target for treating vascular disorders and inflammatory conditions like sepsis. This study aimed to enhance the binding affinity of recombinant Ang1 variants to the Tie2 and explore their therapeutic potential. Structural insights from the Ang1-Tie2 complex enabled the identification of key residues within the Ang1 receptor binding domain (RBD) critical for Tie2 interaction. Molecular dynamics simulations revealed that Met
2. Impact of Fluconazole Resistance on the Outcomes of Patients With Candida parapsilosis Bloodstream Infections: A Retrospective Multicenter Study.
In 457 C. parapsilosis candidemia cases, fluconazole resistance did not increase 30-day mortality, while age, solid tumors, prior antifungal exposure, and septic shock did. Fluconazole-resistant infections had significantly higher 1-year recurrence.
Impact: Clarifies that resistance status should not drive escalation solely for short-term mortality concerns but highlights the need to mitigate recurrence in resistant infections, informing stewardship and follow-up strategies.
Clinical Implications: Echinocandins remain appropriate for resistant isolates without expecting mortality benefit over fluconazole in susceptible cases; however, clinicians should plan for source control, device management, and vigilant follow-up to reduce 1-year recurrence.
Key Findings
- Among 457 patients, 30-day all-cause mortality was similar between FLZR-CP (28.6%) and FLZS-CP (28.4%).
- Independent mortality predictors were age, solid tumor, prior antifungal treatment, and septic shock, not fluconazole resistance or initial antifungal class.
- Fluconazole resistance was associated with higher 1-year recurrence (OR 7.37; 95% CI, 2.11–25.80).
Methodological Strengths
- Multicenter cohort with 457 patients across two countries
- Multivariable modeling and propensity score-matched analyses
Limitations
- Retrospective design with potential residual confounding
- Practice patterns and antifungal choices may vary across centers and time
Future Directions: Prospective studies to identify drivers of recurrence in resistant C. parapsilosis, evaluate duration/step-down strategies, and assess catheter management and source control interventions.
BACKGROUND: This study assesses the impact of fluconazole resistance on 30-day all-cause mortality and 1-year recurrence in patients with Candida parapsilosis bloodstream infections (BSI). METHODS: A multicenter retrospective study was performed at 3 hospitals in Italy and Spain between 2018 and 2022. Adult patients with positive blood cultures for C. parapsilosis who received appropriate targeted therapy with either echinocandins or fluconazole were included. RESULTS: Among 457 patients, 196 (42.9%) had fluconazole-resistant C. parapsilosis (FLZR-CP) BSI and 261 (57.1%) had fluconazole-susceptible C. parapsilosis (FLZS-CP) BSI. All FLZR-CP patients received targeted echinocandins, while FLZS-CP patients received either echinocandins (60.5%) or fluconazole (39.5%). Unadjusted 30-day all-cause mortality rates were 28.6% for FLZR-CP and 28.4% for FLZS-CP (log-rank test, P = .998). In multivariable analysis, increased mortality was associated with age (adjusted hazard ratio [aHR] 1.03 per year; 95% confidence interval [CI], 1.01-1.05; P = .0005), solid tumor (aHR 1.91; 95% CI, 1.06-3.46; P = .0302), previous antifungal treatment (aHR 1.84; 95% CI, 1.12-3.10; P = .0192), and septic shock (aHR 2.39; 95% CI, 1.42-4.06; P = .0010), but not fluconazole resistance (aHR 1.00; 95% CI, .62-1.63; P = .9864) nor the type of initial antifungal therapy (aHR 1.46; 95% CI, .69-3.06; P = .3202). Propensity score-matched analysis showed no 30-day all-cause mortality difference between echinocandin-treated FLZR-CP and fluconazole-treated FLZS-CP patients (HR 0.81; 95% CI, .37-1.75; P = .5915). However, a higher 1-year recurrence risk was observed in FLZR-CP patients (odds ratio, 7.37; 95% CI, 2.11-25.80; P = .0018). CONCLUSIONS: Our results suggest that fluconazole resistance is not associated with a higher mortality risk in patients with C. parapsilosis BSI, though 1-year recurrence rates were higher in the FLZR-CP group.
3. Early systemic insults following severe sepsis-associated encephalopathy of critically ill patients: association with mortality and awakening-an analysis of the OUTCOMEREA database.
In 995 ICU patients with severe SAE, 89% had at least one early systemic insult. Lack of correction by day 3 of hypotension, hypoxemia, temperature abnormalities, or dysglycemia independently predicted higher mortality and reduced awakening.
Impact: Provides actionable physiologic targets within the first 72 hours to potentially improve neurologic and survival outcomes in severe SAE, informing ICU management bundles.
Clinical Implications: Aggressively monitor and correct blood pressure, oxygenation, temperature, and glycemia in the first 72 hours of ICU care for severe SAE to improve survival and awakening probability.
Key Findings
- Among 995 severe SAE patients, 89% had at least one early systemic insult persisting to day 3.
- Failure to correct by day 3: hypotension (aHR 1.77), oxygenation abnormalities (aHR 1.78), temperature abnormalities (aHR 1.46), and dysglycemia (aHR 1.41) independently predicted mortality.
- Persistent abnormalities in blood pressure, temperature, and glycemia were associated with reduced chances of awakening.
Methodological Strengths
- Large sample from a prospective multicenter ICU database
- Adjusted hazard models examining time-bound physiologic targets
Limitations
- Retrospective analysis with potential residual confounding
- Use of Sepsis 2.0 definitions may limit alignment with current Sepsis-3 criteria
Future Directions: Prospective interventional studies testing bundles that target early correction of systemic insults in SAE, and validation across diverse ICUs and with Sepsis-3 definitions.
BACKGROUND: Sepsis-associated encephalopathy (SAE) may be worsened by early systemic insults. We aimed to investigate the association of early systemic insults with outcomes of critically ill patients with severe SAE. METHODS: We performed a retrospective analysis using data from the French OUTCOMEREA prospective multicenter database. We included patients hospitalized in intensive care unit (ICU) for at least 48 h with severe SAE (defined by a score on the Glasgow Coma Scale (GCS) ≤ 13 and severe sepsis or septic shock (SEPSIS 2.0 criteria)) requiring invasive ventilation and who had no primary brain injury. We analyzed early systemic insults (abnormal glycemia (< 3 mmol/L or ≥ 11 mmol/L), hypotension (diastolic blood pressure ≤ 50 mmHg), temperature abnormalities (< 36 °C or ≥ 38.3 °C), anemia (hematocrit < 21%), dysnatremia (< 135 mmol/L or ≥ 145 mmol/L), oxygenation abnormalities (PaO RESULTS: We included 995 patients with severe SAE, of whom 883 (89%) exhibited at least one early systemic insult that persisted through day 3. Compared to non-survivors, survivors had significantly less early systemic insults (hypoglycemia, hypotension, hypothermia, and anemia) within the first 48 h of ICU admission. The absence of correction of the following systemic insults at day 3 was independently associated with mortality: blood pressure (adjusted hazard ratio (aHR) = 1.77, 95% confidence interval (CI) 1.34-2.34), oxygenation (aHR = 1.78, 95% CI 1.20-2.63), temperature (aHR = 1.46, 95% CI 1.12-1.91) and glycemia (aHR = 1.41, 95% CI 1.10-1.80). Persistent abnormal blood pressure, temperature and glycemia at day 3 were associated with decreased chances of awakening. CONCLUSIONS: In patients with severe SAE, the persistence of systemic insults within the first three days of ICU admission is associated with increased mortality and decreased chances of awakening.